Department of Thoracic Surgery Clinic, Istanbul Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkiye.
Department of Pathology, Istanbul Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkiye.
J Coll Physicians Surg Pak. 2023 Jul;33(7):765-769. doi: 10.29271/jcpsp.2023.07.765.
To investigate the prognostic significance of STAS (Spread through air spaces) and its effect on survival in the various types of non-small cell lung cancer (NSCLC).
Descriptive analytical study. Place and Duration of the Study: Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkiye, between 2018 and 2021.
Early-stage lung cancer patients who underwent lobectomy were included. STAS was defined as presence of tumour cell clumps, solid nests or set of single cells located in airway spaces apart from the main tumour border and determined by pathological work-up. The clinical significance of STAS was investigated by means of histopathological subtype, tumour size, and maximum standardised uptake value (SUVmax) on PET-CT scan in early-stage lung cancer by grouping it as adenocarcinoma and non-adenocarcinoma. Five-year overall and disease-free survival, and recurrence were the outcome measures.
A total of 165 patients were included in the study. No recurrence was observed in 125 patients, 40 patients developed recurrence. Five-year overall survival (OS) was 69.6% in STAS (+) cohort and 74.5% in STAS (-) cohort (p=0.88). Five-year disease-free survival (DFS) was 51.1% in STAS (+) cohort and 73.1% for STAS (-) cohort (p=0.034). While the absence of STAS in the adenocarcinoma group was associated with better DFS, lower SUVMax and smaller tumour size, similar results were not found to be at statistically significant level in the non-adenocarcinoma group.
STAS positivity makes a difference in DFS, tumour size and SUVmax, especially in adenocarcinoma, however, it does not create a significant difference in survival or clinic pathological features in the non-adenocarcinoma.
Lung Cancer, Lobectomy, Spread through air spaces, Survival, Prognosis.
研究在各种非小细胞肺癌(NSCLC)中 STAS(空气传播扩散)的预后意义及其对生存的影响。
描述性分析研究。地点和研究时间:伊斯坦布尔 Kartal Dr. Lutfi Kirdar 城市医院,土耳其,2018 年至 2021 年。
纳入接受肺叶切除术的早期肺癌患者。STAS 定义为肿瘤细胞团、实体巢或一组位于主肿瘤边界外的气道空间中的单个细胞存在,并通过病理检查确定。通过将 STAS 分组为腺癌和非腺癌,研究其在早期肺癌中的组织病理学亚型、肿瘤大小和最大标准化摄取值(SUVmax)对 PET-CT 扫描的临床意义。五年总生存率和无病生存率以及复发是观察终点。
共有 165 名患者纳入研究。125 名患者无复发,40 名患者复发。STAS(+)队列的五年总生存率(OS)为 69.6%,STAS(-)队列为 74.5%(p=0.88)。STAS(+)队列的五年无病生存率(DFS)为 51.1%,STAS(-)队列为 73.1%(p=0.034)。在腺癌组中,STAS 阴性与更好的 DFS、更低的 SUVmax 和更小的肿瘤大小相关,但在非腺癌组中未发现统计学上有意义的结果。
STAS 阳性在 DFS、肿瘤大小和 SUVmax 方面存在差异,尤其是在腺癌中,但在非腺癌中,它在生存或临床病理特征方面没有产生显著差异。
肺癌、肺叶切除术、空气传播扩散、生存、预后。